GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (NAS:ALNY) » Definitions » Total Payout Yield %

ALNY (Alnylam Pharmaceuticals) Total Payout Yield % : 0.00 (As of Dec. 13, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Alnylam Pharmaceuticals Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Alnylam Pharmaceuticals's current Total Payout Yield % is 0.00%.


Alnylam Pharmaceuticals Total Payout Yield % Historical Data

The historical data trend for Alnylam Pharmaceuticals's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Total Payout Yield % Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Payout Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.05 -0.66 - - -

Alnylam Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Alnylam Pharmaceuticals's Total Payout Yield %

For the Biotechnology subindustry, Alnylam Pharmaceuticals's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alnylam Pharmaceuticals's Total Payout Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Alnylam Pharmaceuticals's Total Payout Yield % falls into.



Alnylam Pharmaceuticals Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Alnylam Pharmaceuticals's Total Payout Yield % for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 0 + 0) / 24078.22954
=0.00%

Alnylam Pharmaceuticals's annualized Total Payout Yield % for the quarter that ended in Sep. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0 + 0) * 4 / 35435.14023
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alnylam Pharmaceuticals Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Alnylam Pharmaceuticals Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Alnylam Pharmaceuticals Business Description

Address
675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
Executives
Tolga Tanguler officer: EVP, Chief Commercial Officer 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142
Yvonne Greenstreet officer: EVP, Chief Commercial Officer PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054
Jeffrey V. Poulton officer: Chief Financial Officer 300 THIRD STREET, CAMBRIDGE MA 02142
Pushkal Garg officer: CMO & EVP Dev & Med Affairs C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Dennis A Ausiello director PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Amy W Schulman director PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Pyott David E I director C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612
Phillip A Sharp director BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Indrani Lall Franchini officer: EVP, CLO & Secretary C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Michael W Bonney director 65 HAYDEN AVE, LEXINGTON MA 02421
Akshay Vaishnaw officer: SVP, Clinical Research 300 THIRD STREET, CAMBRIDGE MA 02139
Peter N Kellogg director MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100
Carolyn R Bertozzi director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Charles Elliott Sigal director 32 BREARLY ROAD, PRINCETON NJ 08540
John Maraganore director, officer: President and CEO 75 SIDNEY ST, CAMBRIDGE MA 02139

Alnylam Pharmaceuticals Headlines